Harmony Biosciences (HRMY)
(Delayed Data from NSDQ)
$37.76 USD
+0.48 (1.29%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $37.75 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Income Statements
Fiscal Year end for Harmony Biosciences Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 582 | 438 | 305 | 160 | 6 |
Cost Of Goods | 121 | 83 | 56 | 28 | 2 |
Gross Profit | 461 | 354 | 250 | 132 | 4 |
Selling & Adminstrative & Depr. & Amort Expenses | 269 | 234 | 162 | 115 | 150 |
Income After Depreciation & Amortization | 192 | 120 | 88 | 17 | -146 |
Non-Operating Income | 5 | 0 | -26 | -26 | 0 |
Interest Expense | 24 | 16 | 24 | 28 | 6 |
Pretax Income | 173 | 105 | 37 | -37 | -152 |
Income Taxes | 45 | -77 | 3 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 129 | 181 | 35 | -37 | -152 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 129 | 181 | 35 | -37 | -152 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 216 | 145 | 109 | 30 | -142 |
Depreciation & Amortization (Cash Flow) | 24 | 25 | 21 | 13 | 4 |
Income After Depreciation & Amortization | 192 | 120 | 88 | 17 | -146 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 60.37 | 61.10 | 59.21 | 25.77 | NA |
Diluted EPS Before Non-Recurring Items | 2.13 | 3.00 | 2.07 | 0.21 | NA |
Diluted Net EPS (GAAP) | 2.13 | 2.97 | 0.58 | -2.48 | NA |
Fiscal Year end for Harmony Biosciences Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 172.81 | 154.62 | 168.41 | 160.27 | 134.22 |
Cost Of Goods | 32.14 | 27.48 | 43.15 | 32.30 | 25.01 |
Gross Profit | 140.67 | 127.13 | 125.26 | 127.97 | 109.21 |
SG&A, R&D, and Dept/Amort Expenses | 119.31 | 75.10 | 85.07 | 63.46 | 62.31 |
Income After SG&A, R&D, and Dept/Amort Expenses | 21.36 | 52.03 | 40.19 | 64.51 | 46.90 |
Non-Operating Income | 4.74 | 4.29 | 0.19 | -9.77 | -0.03 |
Interest Expense | 4.40 | 4.54 | 15.43 | 2.91 | 2.78 |
Pretax Income | 21.69 | 51.79 | 39.69 | 51.83 | 44.10 |
Income Taxes | 10.10 | 13.45 | 13.08 | 13.37 | 9.80 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 11.59 | 38.33 | 26.61 | 38.46 | 34.30 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 11.59 | 38.33 | 26.61 | 38.46 | 34.30 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 57.54 | 57.60 | 58.85 | 60.68 | 60.74 |
Diluted EPS Before Non-Recurring Items | 0.20 | 0.67 | 0.45 | 0.63 | 0.56 |
Diluted Net EPS (GAAP) | 0.20 | 0.67 | 0.46 | 0.63 | 0.56 |